DSP-2230 is a selective small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain.

[1][2] As of June 2014, it is in phase I/phase II clinical trials.

[1][2]

This analgesic-related article is a stub.

You can help Wikipedia by expanding it.